ArticleACS chemical neuroscience2017
Diverse Effects on M
Abstract read
In one paragraph
Article in ACS chemical neuroscience, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
3.7field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 57 citations in OpenAlex.
- Trial
- Article
- Functional Evaluation of Tetrahydroisoquinoline-Derived Ligands Reveals Distinct Modulatory Profiles at the Muscarinic M1 Receptor.ACS medicinal chemistry letters · 2026Article
- Discovery of VU6052254: A Novel, Potent MACS chemical neuroscience · 2025Article
- Application of Deuterium in an MACS chemical neuroscience · 2025Article
- Discovery of VU0467319: an MACS chemical neuroscience · 2025Article
- A golden age of muscarinic acetylcholine receptor modulation in neurological diseases.Nature reviews. Drug discovery · 2024Review
- Discovery of VU6007496: Challenges in the Development of an MACS chemical neuroscience · 2024Article
- Analysing the effect caused by increasing the molecular volume in M1-AChR receptor agonists and antagonists: a structural and computational study.RSC advances · 2024Article
- MProceedings of the National Academy of Sciences of the United States of America · 2023Article
- Design, Synthesis, and Characterization of [Journal of medicinal chemistry · 2022Article
- Targeting the M1 muscarinic acetylcholine receptor in Alzheimer's disease.Neuronal signaling · 2022Review
- Drug Design Targeting the Muscarinic Receptors and the Implications in Central Nervous System Disorders.Biomedicines · 2022Review
- Biased M1 muscarinic receptor mutant mice show accelerated progression of prion neurodegenerative disease.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Discovery of a novel class of heteroaryl-pyrrolidinones as positive allosteric modulators of the muscarinic acetylcholine receptor MBioorganic & medicinal chemistry letters · 2021Article
- Classification models and SAR analysis on CysLT1 receptor antagonists using machine learning algorithms.Molecular diversity · 2021Article
- Development of Novel 4-Arylpyridin-2-one and 6-Arylpyrimidin-4-one Positive Allosteric Modulators of the MChemMedChem · 2021Article
- Translation-Focused Approaches to GPCR Drug Discovery for Cognitive Impairments Associated with Schizophrenia.ACS pharmacology & translational science · 2020Review
- Allosteric Modulators of G Protein-Coupled Dopamine and Serotonin Receptors: A New Class of Atypical Antipsychotics.Pharmaceuticals (Basel, Switzerland) · 2020Review
- Effects of muscarinic MNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 1 institution in 1 country.
Jerri M RookDepartment of Pharmacology, ‡Department of Chemistry, §Vanderbilt Center for Neuroscience Drug Discovery, ∥Vanderbilt Kennedy Center, Vanderbilt University School of Medicine , Nashville, Tennessee 37232-6600, United States.
Masahito AbeDepartment of Pharmacology, ‡Department of Chemistry, §Vanderbilt Center for Neuroscience Drug Discovery, ∥Vanderbilt Kennedy Center, Vanderbilt University School of Medicine , Nashville, Tennessee 37232-6600, United States.
Hyekyung P ChoDepartment of Pharmacology, ‡Department of Chemistry, §Vanderbilt Center for Neuroscience Drug Discovery, ∥Vanderbilt Kennedy Center, Vanderbilt University School of Medicine , Nashville, Tennessee 37232-6600, United States.
Kellie D NanceDepartment of Pharmacology, ‡Department of Chemistry, §Vanderbilt Center for Neuroscience Drug Discovery, ∥Vanderbilt Kennedy Center, Vanderbilt University School of Medicine , Nashville, Tennessee 37232-6600, United States.
Vincent B LuscombeDepartment of Pharmacology, ‡Department of Chemistry, §Vanderbilt Center for Neuroscience Drug Discovery, ∥Vanderbilt Kennedy Center, Vanderbilt University School of Medicine , Nashville, Tennessee 37232-6600, United States.
Jeffrey J AdamsDepartment of Pharmacology, ‡Department of Chemistry, §Vanderbilt Center for Neuroscience Drug Discovery, ∥Vanderbilt Kennedy Center, Vanderbilt University School of Medicine , Nashville, Tennessee 37232-6600, United States.
Jonathan W DickersonDepartment of Pharmacology, ‡Department of Chemistry, §Vanderbilt Center for Neuroscience Drug Discovery, ∥Vanderbilt Kennedy Center, Vanderbilt University School of Medicine , Nashville, Tennessee 37232-6600, United States.
Daniel H RemkeDepartment of Pharmacology, ‡Department of Chemistry, §Vanderbilt Center for Neuroscience Drug Discovery, ∥Vanderbilt Kennedy Center, Vanderbilt University School of Medicine , Nashville, Tennessee 37232-6600, United States.
Pedro M Garcia-BarrantesDepartment of Pharmacology, ‡Department of Chemistry, §Vanderbilt Center for Neuroscience Drug Discovery, ∥Vanderbilt Kennedy Center, Vanderbilt University School of Medicine , Nashville, Tennessee 37232-6600, United States.
Darren W EngersDepartment of Pharmacology, ‡Department of Chemistry, §Vanderbilt Center for Neuroscience Drug Discovery, ∥Vanderbilt Kennedy Center, Vanderbilt University School of Medicine , Nashville, Tennessee 37232-6600, United States.
Julie L EngersDepartment of Pharmacology, ‡Department of Chemistry, §Vanderbilt Center for Neuroscience Drug Discovery, ∥Vanderbilt Kennedy Center, Vanderbilt University School of Medicine , Nashville, Tennessee 37232-6600, United States.
Sichen ChangDepartment of Pharmacology, ‡Department of Chemistry, §Vanderbilt Center for Neuroscience Drug Discovery, ∥Vanderbilt Kennedy Center, Vanderbilt University School of Medicine , Nashville, Tennessee 37232-6600, United States.
Jarrett J FosterDepartment of Pharmacology, ‡Department of Chemistry, §Vanderbilt Center for Neuroscience Drug Discovery, ∥Vanderbilt Kennedy Center, Vanderbilt University School of Medicine , Nashville, Tennessee 37232-6600, United States.
Anna L BlobaumDepartment of Pharmacology, ‡Department of Chemistry, §Vanderbilt Center for Neuroscience Drug Discovery, ∥Vanderbilt Kennedy Center, Vanderbilt University School of Medicine , Nashville, Tennessee 37232-6600, United States.
Colleen M NiswenderDepartment of Pharmacology, ‡Department of Chemistry, §Vanderbilt Center for Neuroscience Drug Discovery, ∥Vanderbilt Kennedy Center, Vanderbilt University School of Medicine , Nashville, Tennessee 37232-6600, United States.
Carrie K JonesDepartment of Pharmacology, ‡Department of Chemistry, §Vanderbilt Center for Neuroscience Drug Discovery, ∥Vanderbilt Kennedy Center, Vanderbilt University School of Medicine , Nashville, Tennessee 37232-6600, United States.
P Jeffrey ConnDepartment of Pharmacology, ‡Department of Chemistry, §Vanderbilt Center for Neuroscience Drug Discovery, ∥Vanderbilt Kennedy Center, Vanderbilt University School of Medicine , Nashville, Tennessee 37232-6600, United States.
Craig W LindsleyDepartment of Pharmacology, ‡Department of Chemistry, §Vanderbilt Center for Neuroscience Drug Discovery, ∥Vanderbilt Kennedy Center, Vanderbilt University School of Medicine , Nashville, Tennessee 37232-6600, United States.ORCID 0000-0003-0168-1445
Vanderbilt University · US
Funding
Research Project: Sensory and Multisensory Contributions to AutismU54HD083211 · NICHD · VANDERBILT UNIVERSITY MEDICAL CENTER · PI DYKENS, ELISABETH MAY · 2015 to 2019
$7.1MSafety and tolerability testing of VU0467319: an M1 PAM for clinical developmentU19MH106839 · NIMH · VANDERBILT UNIVERSITY · PI CONN, P JEFFREY · 2015 to 2017
$5.3MSelective M1 mAChR allosteric modulators for the treatment of schizophreniaR01MH082867 · NIMH · VANDERBILT UNIVERSITY · PI LINDSLEY, CRAIG · 2008 to 2017
$3.7MmGlu Allosteric Modulation in Neurodegenerative DiseasesR01AG051626 · NIA · VANDERBILT UNIVERSITY · PI ROOK, JERRI MICHELLE · 2016 to 2020
$2.0MNIA NIH HHS R01 AG051626NICHD NIH HHS U54 HD083211NIMH NIH HHS R01 MH082867NIMH NIH HHS U19 MH106839
Abstract
Both historical clinical and recent preclinical data suggest that the M
Indexed as
Drug DiscoveryAllosteric RegulationAnimalsHumansMiceMuscarinic AgonistsRatsReceptor, Muscarinic M1Structure-Activity RelationshipMuscarinic AgonistsReceptor, Muscarinic M1agonistago-PAMM1muscarinic acetylcholine receptorpositive allosteric modulator (PAM)seizure
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.